Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.
Meghna JaniWilliam G DixonLianne Kersley-FleetIan N BruceHector ChinoyAnne BartonMark LuntKath Watsonnull nullnull nullDeborah P M SymmonsKimme L HyrichPublished in: RMD open (2017)
In one of the largest biological registers, the absolute risk of both events is low. The addition of TNFi to nbDMARD does not alter the risk of either event in patients with RA selected for TNFi. This is the first study to assess the risk of these outcomes in a prospective, observational cohort.